Structural & Congenital Heart Disease

Patients who remain in the hospital for longer than three days following transcatheter aortic valve replacement (TAVR) are at a 45 percent increased risk of death within one year versus those discharged sooner after the procedure, a new analysis found.

The global market for transcatheter treatment of the mitral and aortic valves is expected to double over the next five years, according to a new report from BCC Research. The industry analysis projects an increase from $4 billion in 2018 to $8 billion in 2023, at a compound annual growth rate (CAGR) of 14.8 percent.

ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

More than two years after a major New England Journal of Medicine study declared arthritis drug Celebrex safe for use in heart patients, new research published in JACC: Basic to Translational Science Feb. 22 suggests the drug might actually raise users’ risk for heart valve calcification.

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

P2Y12 inhibitor initiation with clopidogrel using a loading dose (LD) is no more effective in reducing ischemic events or adverse outcomes in transcatheter aortic valve implantation (TAVI) patients than initiating the therapy without a loading dose, according to research published in the American Journal of Cardiology Feb. 10.

A Danish study of 400 patients with infective endocarditis has concluded oral delivery of antibiotics to treat the disease yields similar safety and efficiency as administering the drugs intravenously.

An internal review by Johns Hopkins All Children’s Hospital uncovered 13 cases in which heart surgery patients were harmed by medical care from 2015 to 2018 but that went unreported until recently. Florida law requires such incidents to be reported within 15 days, according to the Tampa Bay Times.

A four-stage system that quantifies the extent of cardiac changes associated with aortic stenosis was linked to the odds of death and readmission following transcatheter aortic valve replacement (TAVR), a finding that may aid cardiologists in making prognoses and engaging in shared decision-making with patients.

Although octogenarians undergoing transcatheter or surgical aortic valve replacement (TAVR or SAVR) experienced similar rates of in-hospital mortality and vascular complications, a recent analysis from the National Inpatient Sample concluded patients who received the less-invasive procedure had shorter hospital stays and fared better for a range of other outcomes.

A patient’s degree of frailty could predict their functional outcomes in the year following transcatheter or surgical aortic valve repair (TAVR or SAVR), according to research out of Beth Israel Deaconess Medical Center in Boston.

Johns Hopkins All Children’s Hospital in St. Petersburg, Florida, could lose its Medicare funding if it doesn’t shape up after a recent inspection found serious problems at the institution, The Tampa Bay Times reported.